Clinical efficacy of moxibustion combined Valsartan in the treatment of early diabetic nephropathy
HUANG Hai1,2 GUO Yi2,3 CHEN Li4 JIN Jingsong2,5
1.Department of Massage Rehabilitation, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430074, China;
2.Hubei Academy of Traditional Chinese Meicine, Hubei Province, Wuhan 430074, China;
3.Department of Endocrinology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430074, China;
4.College of Acupuncture and Orthopedics, Hubei University of Chinese Meicine, Hubei Province, Wuhan 430061, China;
5.Department of Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430074, China
Abstract:Objective To observe the clinical efficacy of moxibustion combined Valsartan in the treatment of early diabetic nephropathy (DN). Methods From August 2018 to October 2019, 48 patients with early DN who diagnosed and treated in Department of Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine were selected as the study subjects. They were divided into the control group and the observation group according to the random table number method,with 24 cases in each group. The control group was given Valsartan on the basis of basic treatment, and the observation group was treated with moxibustion on the basis of the control group. Four weeks for treatment. The urine volume during 24 hours (24 h-UV), urine protein during 24 hours (24 h-UP), microalbuminuria (MAU), urinary transferrin (TRF), urinary α1 microglobulin (α1-MG), urinary retinol-binding protein (RBP), blood urea nitrogen (BUN), serum creatinine (Scr) levels were compared before and after treatment between two groups. Results After treatment, 24 h-UV, 24 h-UP, MAU, TRF, α1-MG, RBP, BUN and Scr levels in two groups were lower than those before treatment (all P < 0.05). 24 h-UV, 24 h-UP, MAU, α1-MG and RBP levels in the observation group were lower than those in the control group(all P < 0.05); but there were no statistically significant differences in BUN, Scr and TRF levels (P > 0.05). Conclusion Moxibustion combined Valsartan can effectively reduce the excretion of urinary microprotein during early DN and alleviate renal kidney damage,so it is worthy of clinical application and research.